Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Form 8 (OPD) - Replacement

16 Nov 2021 07:00

RNS Number : 5075S
Sensyne Health PLC
16 November 2021
 

THIS ANNOUNCEMENT REPLACES THE FORM 8 (OPD) ANNOUNCEMENT RELEASED UNDER RNS NUMBER 2902S ON 12 NOVEMBER 2021.

 

The following correction has been made to reflect the correct position as at 11 November 2021: the interests in ordinary shares of Sensyne Health plc held by Lord Paul Drayson and his close relatives, related trusts and connected persons. All other information remains unchanged.

 

CORRECTION: FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

LORD PAUL DRAYSON

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

SENSYNE HEALTH PLC

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

11 NOVEMBER 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary shares of 10 pence each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

40,594,574*

24.63*

Nil

-

(2) Cash-settled derivatives:

 

Nil

-

Nil

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

-

Nil

-

 

TOTAL:

40,594,574

24.63

Nil

-

 

*Figure and percentage include holdings of Lord Paul Drayson as well as those of his close relatives, related trusts and connected persons

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Description of option / award

Number of ordinary Sensyne shares of 10 pence each under option / award

Date of grant

Exercise price

Vesting date

Lapse date

Sensyne Value Creation Plan (VCP)*

25,000 units

30 April 2021

175 pence or higher

22 July 2025

N/A

Sensyne Health Share Option Plan 2018

214,286 ordinary shares

17 August 2018

175 pence

17 August 2019

17 August 2028

 

\* The VCP is represented by a total of 100,000 plan units with participants permitted to share a pool of value created from the growth in value of Sensyne share capital after a five-year period ending on 23 July 2025.

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

None

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

12 November 2021

Contact name:

Lord Paul Drayson

Telephone number:

+44 330 058 1845

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCFIFEELRLRLIL
Date   Source Headline
5th Feb 20217:00 amRNSManagement appointments
3rd Feb 20217:00 amRNSLaunch of AI algorithm for patient management
21st Jan 20217:00 amRNSSensyne Health Interim Results
20th Jan 20217:00 amRNSSensyne signs SRA with Wolverhampton NHS Trust
19th Jan 202111:06 amRNSHolding(s) in Company
15th Jan 20214:41 pmRNSSecond Price Monitoring Extn
15th Jan 20214:36 pmRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSSensyne launches MagnifEye smartphone app
13th Jan 20212:58 pmRNSHolding(s) in Company
11th Jan 20217:00 amRNSNotice of Interim Results
7th Jan 20215:12 pmRNSHolding(s) in Company
7th Jan 20215:09 pmRNSHolding(s) in Company
4th Jan 20213:06 pmRNSResult of General Meeting & Fundraising Completion
4th Jan 20213:05 pmRNSResult of Open Offer
18th Dec 20207:00 amRNSSensyne Health appoints Non-Executive Director
15th Dec 20207:00 amRNSLaunch of First Digital Health Product in the US
14th Dec 20207:00 amRNSPublication of Circular and General Meeting Notice
9th Dec 202011:06 amRNSSecond Price Monitoring Extn
9th Dec 202011:01 amRNSPrice Monitoring Extension
9th Dec 20209:05 amRNSSecond Price Monitoring Extn
9th Dec 20209:00 amRNSPrice Monitoring Extension
9th Dec 20207:00 amRNSSuccessful completion of Fundraise
8th Dec 20205:36 pmRNSProposed Fundraising
25th Nov 20207:00 amRNSSensyne Health Agreement with Hampshire NHS Trust
17th Nov 20202:05 pmRNSSecond Price Monitoring Extn
17th Nov 20202:00 pmRNSPrice Monitoring Extension
16th Nov 20207:02 amRNSSensyne Health achieves 5 million patient target
16th Nov 20207:00 amRNSSensyne Health Agreement with Somerset NHS Trust
13th Nov 20207:00 amRNSSensyne Health appoints President, North America
2nd Nov 20207:00 amRNSCOVID-19 testing study at University of Oxford
30th Oct 20204:33 pmRNSResult of AGM
28th Oct 20207:00 amRNSSensyne Health Agreement with Microsoft
26th Oct 20207:00 amRNSSensyne Health Agreement with Milton Keynes UH
23rd Oct 20207:00 amRNSSensyne Health agreement with Bristol Myers Squibb
6th Oct 20207:00 amRNSAnnual Report and Accounts and Notice of AGM
5th Oct 20204:40 pmRNSSecond Price Monitoring Extn
5th Oct 20204:35 pmRNSPrice Monitoring Extension
1st Oct 20206:07 pmRNSHolding(s) in Company
1st Oct 20202:00 pmRNSAgreement with NHS Greater Glasgow and Clyde
30th Sep 20201:12 pmRNSCollaboration with the University of Oxford
30th Sep 20207:01 amRNSSensyne Health Long Term Incentive Plan
30th Sep 20207:00 amRNSSensyne Health Full Year Results
29th Sep 202011:55 amRNSHolding(s) in Company
29th Sep 20209:46 amRNSHolding(s) in Company
23rd Sep 20207:00 amRNSNotice of Full Year Results
10th Sep 20207:00 amRNSSensyne Health appoints Chief Operating Officer
3rd Sep 20207:00 amRNSUK launch of ‘SENSE’ in partnership with Microsoft
20th Aug 20209:05 amRNSSecond Price Monitoring Extn
20th Aug 20209:00 amRNSPrice Monitoring Extension
19th Aug 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.